Plavix case settled before Supreme Court of Canada hearing

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Plavix case settled before Supreme Court of Canada hearing

A case that was expected to provide guidance on Canada's "promise" doctrine of utility and the test for sound prediction of utility has been settled a day before it was due to be argued at a Supreme Court hearing

plavix.jpg

On November 3, Apotex discontinued its appeal to the Supreme Court of Canada regarding the validity of Sanofi-Aventis' patent claiming clopidogrel bisulfate, which is marketed as Plavix. As a result, the Supreme Court hearing scheduled for November 4 has been cancelled.

Plavix is used to prevent blood clots after a heart attack or stroke.

Observers were hoping the case would provide some certainty around the scope of the utility requirement. In an amicus brief in the case, AIPPI noted that following the Supreme Court of Canada’s decisions in AZT in 2002 and Viagra in 2012 “there has been uncertainty with respect to the precise scope of the utility requirement under Canadian law and in particular the extent to which the utility of a patented invention should be disclosed or supported in the patent specification.”

In AZT, the Court stated that utility must either be demonstrated or be a sound prediction based on information and expertise available at the filing date. In Viagra, the Court declined to decide the scope of any disclosure requirement associated with “sound prediction”. The brief stated that this “remains an open question in the jurisprudence of this Court, and an area of significant uncertainty in Canadian law”.

Other organisations that filed briefs in the case include BIOTECanada, Canada’s Research-Based Pharmaceutical Companies, the Centre for Intellectual Property Policy, the Canadian Generic Pharmaceutical Association and FICPI.

more from across site and SHARED ros bottom lb

More from across our site

David Stone, a highly influential figure at legacy firm Allen & Overy, has joined White & Case in what is a major move early in 2025
While business has been tough, foreign law firms with IP practices that have decided to stay put in China reveal why they are optimistic
Managing IP will host a ceremony in London on April 10 to reveal the winners of the EMEA Awards 2025
The Intellectual Property Judges' Association wrote to the European Commission just days before the proposals were shelved, it can be revealed
Karla Hughes and Adrian Dykes also join the former global IP head as partners in London, while another partner has left for Clifford Chance
A law firm restricting its employees’ use of AI, a leadership change at Siemens, and ‘probably’ the best trademark news Carlsberg could hope for, were among the top talking points
Former USPTO director Vidal, who rejoined Winston & Strawn after leaving the agency, explains why she got involved in an amicus brief related to jury instructions and Section 101
The judgment clarifies that being employed by a company does not necessarily undermine someone’s independence and ability to appear in court
The EU scrapping a controversial FRAND regulation gives the bloc a chance to properly engage with stakeholders to determine an appropriate way forward
Judd Lauter, who helped his client get a copyright registration for a creative work comprising of AI-generated parts, explains how his team obtained the registration
Gift this article